| Old Articles: <Older 5011-5020 Newer> |
|---|
 |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.   |
The Motley Fool
August 5, 2008
Brian Lawler |
An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone. |
The Motley Fool
August 5, 2008
Brian Orelli |
No Slowdown for China Medical The great Chinese crash of 2008 hasn't yet hit China Medical Technologies. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
The Motley Fool
August 4, 2008
Brian Lawler |
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
August 1, 2008
Brian Lawler |
Holy Moley, CV Therapeutics! With big successes on the regulatory and financial fronts, CV Therapeutics has had a quarter where everything went right. |
The Motley Fool
August 1, 2008
Brian Orelli |
Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line. |
The Motley Fool
August 1, 2008
Brian Lawler |
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
| <Older 5011-5020 Newer> Return to current articles. |
